{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vasoactive+intestinal+peptide",
    "query": {
      "intervention": "vasoactive intestinal peptide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vasoactive+intestinal+peptide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T11:41:16.844Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04433546",
      "title": "Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome",
        "Coronavirus",
        "Hypoxic Respiratory Failure",
        "Hypoxemic Respiratory Failure",
        "Respiratory Complication",
        "Respiratory Insufficiency",
        "Cardiac Dysfunction",
        "Pneumonia",
        "Pulmonary Edema",
        "Pulmonary Inflammation",
        "Respiratory Failure",
        "Cytokine Storm",
        "COVID 19",
        "SARS-CoV-2",
        "Cardiac Event",
        "Cardiac Complication",
        "Cardiac Failure",
        "Cardiac Infarct"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        },
        {
          "name": "Low Dose (10 mg) Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-07-15",
      "completion_date": "2020-12-02",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433546"
    },
    {
      "nct_id": "NCT04360096",
      "title": "Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV 2",
        "COVID",
        "ARDS",
        "ALI",
        "Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)",
        "Dyspnea"
      ],
      "interventions": [
        {
          "name": "ZYESAMI™ (aviptadil acetate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Nebulized administration of ZYESAMI™ or Placebo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "APR Applied Pharma Research s.a.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 144,
      "start_date": "2021-02-15",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-02-03",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 13,
      "location_summary": "Fullerton, California • Irvine, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Winfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04360096"
    },
    {
      "nct_id": "NCT03315507",
      "title": "A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "PB1046 Subcutaneous Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-10-20",
      "completion_date": "2019-08-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315507"
    },
    {
      "nct_id": "NCT00004494",
      "title": "Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sepsis",
        "Respiratory Distress Syndrome",
        "Respiratory Distress Syndrome, Adult"
      ],
      "interventions": [
        {
          "name": "vasoactive intestinal peptide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "1998-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-05-04",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 2,
      "location_summary": "Northport, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "Northport",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004494"
    },
    {
      "nct_id": "NCT03556020",
      "title": "Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 35,
      "start_date": "2018-07-15",
      "completion_date": "2022-01-07",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03556020"
    },
    {
      "nct_id": "NCT01563757",
      "title": "Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fontan Physiology Patients With PB or PLE",
        "Fontan Physiology Patients Without PB or PLE"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 20,
      "start_date": "2012-03",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-10-29",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01563757"
    },
    {
      "nct_id": "NCT04453839",
      "title": "ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Critical COVID-19 With Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "ZYESAMI (aviptadil acetate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "APR Applied Pharma Research s.a.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-02-03",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 25,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Baldwin Park, California + 20 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04453839"
    },
    {
      "nct_id": "NCT04788277",
      "title": "Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "79 Years",
        "sex": "MALE",
        "summary": "50 Years to 79 Years · Male only"
      },
      "enrollment_count": 810,
      "start_date": "2020-02-26",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04788277"
    },
    {
      "nct_id": "NCT06729606",
      "title": "Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Aviptadil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aviptadil Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 471,
      "start_date": "2021-04-20",
      "completion_date": "2022-11-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06729606"
    },
    {
      "nct_id": "NCT03898856",
      "title": "Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Diarrhea of Unknown Origin"
      ],
      "interventions": [
        {
          "name": "Crofelemer",
          "type": "DRUG"
        },
        {
          "name": "Diagnostic tests for cause of chronic diarrhea",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 93,
      "start_date": "2019-04-01",
      "completion_date": "2025-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-09-10T11:41:16.844Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03898856"
    }
  ]
}